구강 작열감 증후군에서 Pregabalin의 치료 효과
Effectiveness of Pregabalin in Treatment of Burning Mouth Syndrome
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Objectives Burning mouth syndrome (BMS) is a chronic pain disorderinvolving a burning sensation of the oral cavity without any identifiable oral lesion. Accordingto the recent studies, the pathogenesis of BMS is presumed to be caused by a neuropathic condition. Gabapentin and pregabalin have been used for various neuropathic pains, but pregabalinhas several pharmacokinetic advantages over gabapentin. To our best knowledge, there areno recent studies reported on the administration of pregabalin in treating BMS in Korea. Therefore, in this study, we investigated the therapeutic effect of pregabalin in treating BMS. Subjects and Method We chose as candidates 33 patients diagnosed as BMS and took pregabalinfor more than four weeks. Pregabalin was administered at 75 mg once a day for 2 to 4weeks at first, and then the dose was modified depending on whether or not symptoms improved. Effectiveness of treatment was evaluated in the way that the patients subjectively answeredwhether or not symptoms were improved. Results A total of 21 (63.6%) out of 33 patients were responsive to the treatment. Among those,at the last follow-up, 8 patients (38.1%) showed slight improvement, and 13 patients (61.9%)showed mostly improvement or disappearance of symptoms. The average time interval fromstarting pregabalin to the first symptom improvement was 50.1 days, and most patients showedsymptom improvement within 8 weeks. Conclusion This study concludes that pregabalin can be added as a meaningful option inthe treatment of BMS. The additional double-blind clinical study should be followed to furtherprove the effectiveness of pregabalin.
Abstract
Background and Objectives Burning mouth syndrome (BMS) is a chronic pain disorderinvolving a burning sensation of the oral cavity without any identifiable oral lesion. Accordingto the recent studies, the pathogenesis of BMS is presumed to be caused by a neuropathic condition. Gabapentin and pregabalin have been used for various neuropathic pains, but pregabalinhas several pharmacokinetic advantages over gabapentin. To our best knowledge, there areno recent studies reported on the administration of pregabalin in treating BMS in Korea. Therefore, in this study, we investigated the therapeutic effect of pregabalin in treating BMS. Subjects and Method We chose as candidates 33 patients diagnosed as BMS and took pregabalinfor more than four weeks. Pregabalin was administered at 75 mg once a day for 2 to 4weeks at first, and then the dose was modified depending on whether or not symptoms improved. Effectiveness of treatment was evaluated in the way that the patients subjectively answeredwhether or not symptoms were improved. Results A total of 21 (63.6%) out of 33 patients were responsive to the treatment. Among those,at the last follow-up, 8 patients (38.1%) showed slight improvement, and 13 patients (61.9%)showed mostly improvement or disappearance of symptoms. The average time interval fromstarting pregabalin to the first symptom improvement was 50.1 days, and most patients showedsymptom improvement within 8 weeks. Conclusion This study concludes that pregabalin can be added as a meaningful option inthe treatment of BMS. The additional double-blind clinical study should be followed to furtherprove the effectiveness of pregabalin.
참고문헌 (30)
- Klein B, "Burning mouth syndrome", Dermatol Clin, 38(4), pp.477~483 (2020)
- Scala A, "Update on burning mouth syndrome : Overview and patient management", Crit Rev Oral Biol Med, 14(4), pp.275~291 (2003)
- Ritchie A, "Recent advances in the etiology and treatment of burning mouth syndrome", J Dent Res, 97(11), pp.1193~1199 (2018)
- Jääskeläinen SK, "Pathophysiology of primary burning mouth syndrome", Clin Neurophysiol, 123(1), pp.71~77 (2012)
- Headache Classification Committee of the International Headache Society (IHS), "The international classification of headache disorders, 3rd edition", Cephalalgia, 38(1), pp.1~211 (2018)
- Kolkka-Palomaa M, "Pathophysiology of primary burning mouth syndrome with special focus on taste dysfunction : A review", Oral Dis, 21(8), pp.937~948 (2015)
- Lopez-Jornet P, "Neuropathic pain in patients with burning mouth syndrome evaluated using painDETECT", Pain Med, 18(8), pp.1528~1533 (2017)
- Gurvits GE, "Burning mouth syndrome", World J Gastroenterol, 19(5), pp.665~672 (2013)
- Cui Y, "Efficacy evaluation of clonazepam for symptom remission in burning mouth syndrome : A meta-analysis", Oral Dis, 22(6), pp.503~511 (2016)
- Kisely S, "A systematic review of randomized trials for the treatment of burning mouth syndrome", J Psychosom Res, 86, pp.39~46 (2016)
- Liu YF, "Burning mouth syndrome : A systematic review of treatments", Oral Dis, 24(3), pp.325~334 (2018)
- López-D’alessandro E, "Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of burning mouth syndrome : A randomized, double-blind, placebo controlled trial", Med Oral Patol Oral Cir Bucal, 16(5), pp.e635~e640 (2011)
- Fenelon M, "Painrelieving effects of clonazepam and amitriptyline in burning mouth syndrome : A retrospective study", Int J Oral Maxillofac Surg, 46(11), pp.1505~1511 (2017)
- Johansen ME, "Gabapentinoid use in the United States 2002 through 2015", JAMA Intern Med, 178(2), pp.292~294 (2018)
- Finnerup NB, "Pharmacotherapy for neuropathic pain in adults : A systematic review and meta-analysis", Lancet Neurol, 14(2), pp.162~173 (2015)
- Bockbrader HN, "A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin", Clin Pharmacokinet, 49(10), pp.661~669 (2010)
- López-Jornet P, "Burning mouth syndrome : An update", Med Oral Patol Oral Cir Bucal, 15(4), pp.e562~e568 (2010)
- Speciali JG, "Burning mouth syndrome", Curr Pain Headache Rep, 12(4), pp.279~284 (2008)
- Basbaum AI, "The origin of descending pathways in the dorsolateral funiculus of the spinal cord of the cat and rat : Further studies on the anatomy of pain modulation", J Comp Neurol, 187(3), pp.513~531 (1979)
- -norepinephrine release from rat neocortical slices, "Synapse", 2002, 171~190
- 최효근, "구강 작열감 증후군의 약물적 치료 비교 연구", 대한이비인후-두경부외과학회지, 55(11), pp.707~711 (2012), 대한이비인후과학회[DOI]
- Heckmann SM, "Gabapentin has little or no effect in the treatment of burning mouth syndrome-results of an open-label pilot study", Eur J Neurol, 13(7), pp.e6~e7 (2006)
- Kim MJ, "Treatment outcomes and related clinical characteristics in patients with burning mouth syndrome", Oral Dis, 27(6), pp.1507~1518 (2021)
- Ito M, "Five patients with burning mouth syndrome in whom an antidepressant (serotonin-noradrenaline reuptake inhibitor) was not effective, but pregabalin markedly relieved pain", Clin Neuropharmacol, 38(4), pp.158~161 (2015)
- Saliha Yeter Amasyalı, "Effectiveness of Pregabalin for Treatment of Burning Mouth Syndrome", Clinical Psychopharmacology and Neuroscience, 17(1), pp.139~142 (2019), 대한정신약물학회[DOI]
- Derry S, "Pregabalin for neuropathic pain in adults", Cochrane Database Syst Rev, 1(1), pp.CD007076~ (2019)
- 이정훈, "구강 작열감 증후군", 임상이비인후과, 21(2), pp.211~220 (2010), 대한이비인후과학회 부산,울산,경남 지부회[DOI]
- Azzi L, "Is there an association between drugs and burning mouth syndrome? A case-control study", Oral Dis, 25(6), pp.1634~1644 (2019)
- Neil-Dwyer G, "ACE inhibitors in hypertension:Assessment of taste and smell function in clinical trials", J Hum Hypertens, 3(Suppl 1), pp.169~176 (1989)
- Salort-Llorca C, "Drug-induced burning mouth syndrome : A new etiological diagnosis", Med Oral Patol Oral Cir Bucal, 13(3), pp.E167~E170 (2008)